AnPac Bio-Medical Science, a cancer screening and detection company, said on Monday that it has filed for registration testing of its Class III, multi-cancer detection device with China's National Medical Products Administration.

Point-of-care diagnostics firm LumiraDx and special purpose acquisition company CA Healthcare Acquisition said on Monday that they have revised the terms of their previously announced merger to lower the equity value of the combined company.

Partek said that it has entered into an agreement with Santa Clara, California-based Agilent Technologies to integrate its Partek Flow bioinformatics software with the Agilent Alissa Clinical Informatics platform, providing an end-to-end analysis workflow that is customizable for Agilent's customers

South Korean diagnostics company Seegene on Wednesday reported a nearly 11 percent year-over-year increase in its second quarter revenues amid higher sales of its infectious disease testing reagents and PCR equipment in Europe and North America.

Tempus said on Tuesday that it has submitted a premarket approval application for its next-generation sequencing-based xT-Onco tumor profiling assay to the US Food and Drug Administration.

Clarified Precision Medicine on Friday said that it has completed its acquisition of molecular diagnostics firm Interpares Biomedicine.

Biocept reported after the close of the market on Monday that its second quarter revenues increased dramatically year over year, as the cancer diagnostics firm continued its provision of COVID-19 testing.

DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.

BioMérieux said on Tuesday that its first quarter 2021 revenues grew approximately 10 percent year over year. The firm also lowered its full-year sales guidance due to uncertainties in the business environment.